140 related articles for article (PubMed ID: 38629576)
1. Virus-like particles derived from bacteriophage MS2 as antigen scaffolds and RNA protective shells.
Naskalska A; Heddle JG
Nanomedicine (Lond); 2024; 19(12):1103-1115. PubMed ID: 38629576
[TBL] [Abstract][Full Text] [Related]
2. VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus.
Tumban E; Peabody J; Tyler M; Peabody DS; Chackerian B
PLoS One; 2012; 7(11):e49751. PubMed ID: 23185426
[TBL] [Abstract][Full Text] [Related]
3. Messenger RNA vaccine based on recombinant MS2 virus-like particles against prostate cancer.
Li J; Sun Y; Jia T; Zhang R; Zhang K; Wang L
Int J Cancer; 2014 Apr; 134(7):1683-94. PubMed ID: 24105486
[TBL] [Abstract][Full Text] [Related]
4. Oral immunization with bacteriophage MS2-L2 VLPs protects against oral and genital infection with multiple HPV types associated with head & neck cancers and cervical cancer.
Zhai L; Yadav R; Kunda NK; Anderson D; Bruckner E; Miller EK; Basu R; Muttil P; Tumban E
Antiviral Res; 2019 Jun; 166():56-65. PubMed ID: 30926288
[TBL] [Abstract][Full Text] [Related]
5. Structural basis for the development of avian virus capsids that display influenza virus proteins and induce protective immunity.
Pascual E; Mata CP; Gómez-Blanco J; Moreno N; Bárcena J; Blanco E; Rodríguez-Frandsen A; Nieto A; Carrascosa JL; Castón JR
J Virol; 2015 Mar; 89(5):2563-74. PubMed ID: 25520499
[TBL] [Abstract][Full Text] [Related]
6. Cell-specific delivery of diverse cargos by bacteriophage MS2 virus-like particles.
Ashley CE; Carnes EC; Phillips GK; Durfee PN; Buley MD; Lino CA; Padilla DP; Phillips B; Carter MB; Willman CL; Brinker CJ; Caldeira Jdo C; Chackerian B; Wharton W; Peabody DS
ACS Nano; 2011 Jul; 5(7):5729-45. PubMed ID: 21615170
[TBL] [Abstract][Full Text] [Related]
7. A novel candidate HPV vaccine: MS2 phage VLP displaying a tandem HPV L2 peptide offers similar protection in mice to Gardasil-9.
Zhai L; Peabody J; Pang YS; Schiller J; Chackerian B; Tumban E
Antiviral Res; 2017 Nov; 147():116-123. PubMed ID: 28939477
[TBL] [Abstract][Full Text] [Related]
8. Production in Saccharomycescerevisiae of MS2 virus-like particles packaging functional heterologous mRNAs.
Legendre D; Fastrez J
J Biotechnol; 2005 May; 117(2):183-94. PubMed ID: 15823407
[TBL] [Abstract][Full Text] [Related]
9. A novel delivery platform based on Bacteriophage MS2 virus-like particles.
Fu Y; Li J
Virus Res; 2016 Jan; 211():9-16. PubMed ID: 26415756
[TBL] [Abstract][Full Text] [Related]
10. Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2.
Tumban E; Muttil P; Escobar CA; Peabody J; Wafula D; Peabody DS; Chackerian B
Vaccine; 2015 Jun; 33(29):3346-53. PubMed ID: 26003490
[TBL] [Abstract][Full Text] [Related]
11. Expression and immunogenicity of a liver stage malaria epitope presented as a foreign peptide on the surface of RNA-free MS2 bacteriophage capsids.
Heal KG; Hill HR; Stockley PG; Hollingdale MR; Taylor-Robinson AW
Vaccine; 1999 Sep; 18(3-4):251-8. PubMed ID: 10506649
[TBL] [Abstract][Full Text] [Related]
12. Immunogenic display of diverse peptides on virus-like particles of RNA phage MS2.
Peabody DS; Manifold-Wheeler B; Medford A; Jordan SK; do Carmo Caldeira J; Chackerian B
J Mol Biol; 2008 Jun; 380(1):252-63. PubMed ID: 18508079
[TBL] [Abstract][Full Text] [Related]
13. Construction of polyomavirus-derived pseudotype virus-like particles displaying a functionally active neutralizing antibody against hepatitis B virus surface antigen.
Pleckaityte M; Bremer CM; Gedvilaite A; Kucinskaite-Kodze I; Glebe D; Zvirbliene A
BMC Biotechnol; 2015 Sep; 15():85. PubMed ID: 26370129
[TBL] [Abstract][Full Text] [Related]
14. A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2.
Tumban E; Peabody J; Peabody DS; Chackerian B
PLoS One; 2011; 6(8):e23310. PubMed ID: 21858066
[TBL] [Abstract][Full Text] [Related]
15. RNA bacteriophage capsid-mediated drug delivery and epitope presentation.
Brown WL; Mastico RA; Wu M; Heal KG; Adams CJ; Murray JB; Simpson JC; Lord JM; Taylor-Robinson AW; Stockley PG
Intervirology; 2002; 45(4-6):371-80. PubMed ID: 12602361
[TBL] [Abstract][Full Text] [Related]
16. Impact of internal RNA on aggregation and electrokinetics of viruses: comparison between MS2 phage and corresponding virus-like particles.
Dika C; Duval JF; Ly-Chatain HM; Merlin C; Gantzer C
Appl Environ Microbiol; 2011 Jul; 77(14):4939-48. PubMed ID: 21622784
[TBL] [Abstract][Full Text] [Related]
17. Biodistribution of Antibody-MS2 Viral Capsid Conjugates in Breast Cancer Models.
Aanei IL; ElSohly AM; Farkas ME; Netirojjanakul C; Regan M; Taylor Murphy S; O'Neil JP; Seo Y; Francis MB
Mol Pharm; 2016 Nov; 13(11):3764-3772. PubMed ID: 27611245
[TBL] [Abstract][Full Text] [Related]
18. Peptide epitope identification by affinity selection on bacteriophage MS2 virus-like particles.
Chackerian B; Caldeira Jdo C; Peabody J; Peabody DS
J Mol Biol; 2011 Jun; 409(2):225-37. PubMed ID: 21501621
[TBL] [Abstract][Full Text] [Related]
19. MS2 Virus-like Particles as a Versatile Peptide Presentation Platform: Insights into the Deterministic Abilities for Accommodating Heterologous Peptide Lengths.
Dang M; Wu LJ; Zhang SR; Zhu JR; Hu YZ; Yang CX; Zhang XY
ACS Synth Biol; 2023 Dec; 12(12):3704-3715. PubMed ID: 37946498
[TBL] [Abstract][Full Text] [Related]
20. Dual-surface-modified bacteriophage MS2 as an ideal scaffold for a viral capsid-based drug delivery system.
Kovacs EW; Hooker JM; Romanini DW; Holder PG; Berry KE; Francis MB
Bioconjug Chem; 2007; 18(4):1140-7. PubMed ID: 17602681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
